Vinaxanthone
目录号 : GC72076Vinaxanthone（SM-345431）是一种强效且选择性的信号素3A、磷脂酶C（PLC）和FabI抑制剂，信号素3A和FabI的IC50分别为0.1-0.2μM和0.9 mM。
Cas No.:133293-89-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Vinaxanthone shows selective inhibitory activity against phospholipase C (PLC) from rat brain, mutine colon 26 Adenocarcinoma and murine fibroblasts NIH3T3 with IC50s being 5.4, 9.3 and 44 μM, respectively[1].
Vinaxanthone (0.1 mg/mL, 24 h) enhances peripheral nerve regeneration and induces small amounts of neovascularization growth into the cornea[4].
Vinaxanthone (0.5 μM, 20 min) may protects from Dox-induced podocyte apoptosis[5].
Vinaxanthone (0.1-1 μM, 24 h) ameliorates the TGF-β1-induced tubular cell characteristic change[6].
Vinaxanthone (SM-345431) (0.1 mg/mL, Subconjunctival injections, every 2 days, 3 weeks) accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model[4].
Vinaxanthone (SEMA3A-I) (20 µg, i.p.) protects from Doxorubicin -induced podocyte injury through an anti-apoptosis mechanism in mouse model of Doxorubicin -induced podocytopathy[5].
References:
[1]. Masahiro Aoki, et al. Structure of a novel phospholipase C inhibitor, vinaxanthone (Ro 09-1450), produced by penicillium vinaceum. Tetrahedron Letters. 1991, 32 (36):4737-4740.
[2]. Liang Zhang, et al. Rewiring of regenerated axons by combining treadmill training with semaphorin3A inhibition. Mol Brain. 2014 Mar 10; 7:14.
[3]. Zheng CJ, et al. Vinaxanthone, a new FabI inhibitor from Penicillium sp. J Antimicrob Chemother. 2009 May;63(5):949-53.
[4]. Omoto M, Yoshida S, Miyashita H, Kawakita T, Yoshida K, Kishino A, Kimura T, Shibata S, Tsubota K, Okano H, Shimmura S. The semaphorin 3A inhibitor SM-345431 accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model. PLoS One. 2012;7(11):e47716.
[5]. Sang Y, et al. Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury. Int J Mol Sci. 2020 Jun 8;21(11):4099.
[6]. Sang Y, et al. Semaporin3A inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. Am J Physiol Renal Physiol. 2021 Dec 1;321(6):F740-F756.
| Cas No. | 133293-89-7 | SDF | |
| 分子式 | C28H16O14 | 分子量 | 576.42 |
| 溶解度 | DMSO : 100 mg/mL (173.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7348 mL | 8.6742 mL | 17.3485 mL |
| 5 mM | 0.347 mL | 1.7348 mL | 3.4697 mL |
| 10 mM | 0.1735 mL | 0.8674 mL | 1.7348 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。